Navigation Links
VerifyNow System

ProductsVerifyNow System
Company Accumetrics
Item VerifyNow System
Features Each single-use disposable assay device, such as the VerifyNow IIb/IIIa or VerifyNow Aspirin Assay, contains all needed reagents to provide analytical results for a specific assay. Assay devices are individually pouched and may be used until the expiration date printed on each kit box and foil pouch.

The assay device consists of the following components:

  • Finger Grip: Each assay device has a handle with which the user can insert or remove the assay device from the assay device port.
  • Staging Well: The blood sample is held in this area for temperature stabilization prior to analysis.
  • Assay Device Spot Code: Each assay device is labeled with a unique spot code. Upon insertion of the assay device into the assay device port, the instrument automatically scans the spot code and determines which assay is being performed, records the lot number, and verifies that the assay device has not expired.
  • Sample Well: The sample well is the area of the assay device where the blood collection tube is inserted. The well contains a Blood Collection Tube Spike for sampling directly from a closed blood collection tube. A protective sheath is removed from the assay device spike before use.
  • Humidity Indicator: Each assay device has a humidity sensor to determine whether the assay device has been exposed to excess humidity.
  • Mixing Chamber/Detection Wells: The wells contain all necessary reagents for the specific assays.
Description The Company's first commercial product is the VerifyNow System, a point-of-care, bedside instrument with single-use, disposable assay devices . The advantages of the VerifyNow System over previous products are direct use of a vacuum-type blood collection tube (whole blood sample) and a result in minutes. VerifyNow IIb/IIIa, the first assay developed for use on the system is to assess GP IIb/IIIa platelet inhibition in response to abciximab or eptifibatide. VerifyNow Aspirin, the second assay developed for use on the system is to aid in the detection of platelet dysfunction due to aspirin ingestion.

The GP IIb/IIIa inhibitor class of intravenous antiplatelet agents, has demonstrated benefit in treating patients undergoing coronary interventions (e.g. PTCA and stent placement) and acute coronary syndromes. Currently available drugs in this class include ReoPro (Centocor), Integrilin (Millenium Pharmaceuticals) and Aggrastat(Merck & Co.). Accumetrics estimates that over 2.5 million patients annually are candidates for intravenous antiplatelet therapy. Data from clinical trials suggest that both the safety and efficacy of these agents are dependent on achieving a specific level of receptor blockade. Since there are individual variations in the response to these agents, Accumetrics' first product is targeted to address this unmet medical need.

Aspirin, the most commonly used antithrombotic medication in the world, prevents heart attack, stroke, and other vascular events by causing platelet dysfunction, so that platelets will not aggregate. Over 20 million people in the U.S. alone take aspirin daily to prevent platelets from clotting. Clinical data shows that not all patients receive the full benefits of aspirin, therefore it is important to ensure that patients are receiving the expected anti-platelet benefits. Accumetrics second product is designed to address this important medical need.

Info Accumetrics
Customer Service: (800) 643-1640

Related medicine products :

1. VerifyNow Aspirin Assay
2. VerifyNow IIb/IIIa Assay
3. VerifyNow Clopidogrel Assay
4. VerifyNow (Ultegra) System
5. Silicone Oil Cannula System - 20 Gauge
6. Silicone Oil Cannula System - 19 Gauge
7. SuperVu Galilean System
8. KOWA nonmyd 7 / VK-2 Digital Imaging System
9. KOWA nonmyd a-D / VK-2 Digital Imaging System
10. Refraction System RT-2100
11. Odyssey Phacoemulsification System
Inquire...
Agarose I (Molecular Biology Grade) - A regular melting temperature agarose for electrophoresis requiring an exceptional level of purity with unequaled performance....
... Blend), is a unique mixture of agarose ... nucleic acids and PCR products. Specially designed ... 1,000 bp. Agarose 3:1 HRB™ displays precise ... fluorescence. The high gel strength allows for ...
... resolves DNA and RNA fragments from 100 ... is a standard melting temperature multi-purpose agarose ... Its high gel strength specification ensures ... nor during Southern and Northern transfers. ...
Medicine Products:
(Date:10/13/2017)... Ky. (PRWEB) , ... October 13, 2017 , ... The ... MPH to become its next President and Chief Executive Officer, succeeding Dr. James C. ... CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of ...
(Date:10/13/2017)... Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD ... dose required and providing a CBD form that can be easily incorporated into liquid ...
(Date:10/13/2017)... N.Y (PRWEB) , ... October 13, 2017 , ... Lori ... became a member of ElderCounsel, a national organization of elder law and special needs ... changing laws and rules. It also provides a forum to network with elder law ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for ... for action towards gender equality at their inaugural Summit in New York City in ... reached a social audience of over 3 million. To watch the Mobilize Women video, ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... -- AVACEN Medical , Inc. (AVACEN) announced that Frost ... Product Innovation Award for Its fibromyalgia pain management device. ... device market research by Frost & Sullivan,s industry experts. ... relief product, the AVACEN 100, offers a safe and effective ... ...
(Date:10/12/2017)... -- West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today announced that it will release third-quarter 2017 ... 26, 2017, and will follow with a conference call ... a.m. Eastern Time. To participate on the call, please ... is 94093362. A ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
Breaking Medicine Technology: